視神経炎治療の世界市場-2023年～2030年

概要

視神経炎とは、眼球の神経が炎症を起こす疾患です。視神経炎は、病気が原因で起こることもあれば、特に原因不明のこともあります。視神経炎を発症した人は、多発性硬化症を発症する可能性があります。視神経炎の最も一般的な症状には、眼球運動時の痛みや片眼の一時的な視力低下があります。

また、視神経炎は治療をしなくても自然に治ることがあります。しかし、視機能が低下している場合は、メチルプレドニゾロンなどのステロイド薬を点滴静注し、ステロイド薬を漸減経口投与するコースをとりますが、この後、このコースをとることで視機能の回復が早まることがわかっています。通常のコースは、ステロイドを3日間点滴し、その後数日間漸減するものです。ステロイド療法に失敗し、重度の視力低下が続く場合、血漿交換療法と呼ばれる治療法で視力が回復する人もいるかもしれないが、血漿交換療法が視神経炎に有効であることはまだ研究で確認されていないです。

市場力学：促進要因

新規治療薬に対する需要の増加

革新的な治療薬に対する需要が増加しており、これが予測期間中の世界市場を牽引すると予想されます。新規治療薬は、より良い疾患管理のための代替または補完的な治療オプションを提供することで、視神経炎の治療に関連するアンメットニーズに対処することを目的としています。

例えば、2023年7月6日、Horizon Therapeutics社は、視神経炎を主な特徴とする視神経脊髄炎スペクトラム障害（NMOSD）患者を対象としたUplizna（inebilizumab-cdon）の後期試験から得られた良好な新規データを発表しました。

さらに、新規治療薬の開発におけるFDA承認など多くの規制当局の承認は、患者の信頼を高め、視神経炎治療においてより良い結果を示しています。例えば、2020年8月14日、FDAはGenentech社のEnspryng（satralizumab-mwge）を抗アクアポリン-4（AQP4）抗体視神経炎成人に対する最初で唯一の皮下治療薬として承認しました。

さらに、視神経炎の有病率の増加、FDA承認の増加、臨床試験の増加、認知度の向上、新薬や治療法の開発における進歩が、予測期間中に市場を牽引すると予想される要因です。

阻害要因

副腎皮質ステロイドの大量投与に伴う合併症や副作用、治療費の高騰、治療のためのより良い治療法の欠如などの要因が、市場の妨げになると予想されます。

目次

第1章 調査手法と調査範囲

第2章 定義と概要

第3章 エグゼクティブサマリー

第4章 市場力学

• 影響要因
  • 促進要因
    • 新規治療薬に対する需要の増加
  • 抑制要因
    • 副腎皮質ステロイドの使用に伴う合併症
  • 機会
  • 影響分析

第5章 産業分析

• ポーターのファイブフォース分析
• サプライチェーン分析
• 価格分析
• 規制分析
• パイプライン分析
• アンメットニーズ
• 特許分析
• ボリューム分析
• DMIオピニオン

第6章 COVID-19分析

第7章 疾患タイプ別

• 網脈管神経炎
• 乳頭炎
• 神経周囲炎
• 網膜神経炎

第8章 治療タイプ別

• 経口副腎皮質ステロイド薬
• 副腎皮質ステロイドの静脈内投与
• その他

第9章 流通チャネル別

• 病院薬局
• 小売薬局
• オンライン薬局

第10章 地域別

• 北米
  • 米国
  • カナダ
  • メキシコ
• 欧州
  • ドイツ
  • 英国
  • フランス
  • イタリア
  • スペイン
  • その他欧州
• 南米
  • ブラジル
  • アルゼンチン
  • その他南米
• アジア太平洋
  • 中国
  • インド
  • 日本
  • オーストラリア
  • その他アジア太平洋地域
• 中東・アフリカ

第11章 競合情勢

• 競合シナリオ
• 市況/シェア分析
• M&A分析

第12章 企業プロファイル

• Pfizer Inc.
  • 会社概要
  • 製品ポートフォリオと説明
  • 財務概要
  • 主な発展
• MERCK & CO., Inc.
• EyePoint Pharmaceuticals, Inc.
• Novartis AG
• Genentech, Inc.
• Mallinckrodt plc
• Alcon Inc.
• NIKSAN PHARMACEUTICAL
• AbbVie Inc.
• Hubei Gedian Humanwell Pharmaceutical Co., Ltd.

第13章 付録

Overview

Optic neuritis is a condition in which the nerve to the eye becomes inflamed or irritated. Optic neuritis is a condition that can happen because of a disease or without any specific known cause. A person who has optic neuritis might go on to develop multiple sclerosis. The most common symptoms of optic neuritis include pain with eye movement and temporary vision loss in one eye.

Moreover, optic neuritis may resolve spontaneously without any treatment. However, if the visual function is poor, a course of a steroid medication such as IV methylprednisolone with a tapering course of oral steroids is given, this afterward has been shown to speed recovery of visual function. The usual course is three days of IV steroids followed by a few days of tapering medication. When steroid therapy fails and severe vision loss persists, a treatment called plasma exchange therapy might help some people recover their vision, but studies have not yet confirmed that plasma exchange therapy is effective for optic neuritis.

Market Dynamics: Drivers

Increasing demand for novel therapeutics

There is an increasing demand for therapeutic innovative medications, which is expected to drive the global market over the forecast period. The novel therapeutics aim to address the unmet needs associated with the treatment of optic neuritis by providing alternative or complementary treatment options for better disease management.

For instance, on July 6, 2023, Horizon Therapeutics shared positive new data from a late-stage study of Uplizna (inebilizumab-cdon) in patients with neuromyelitis optica spectrum disorder (NMOSD) which is majorly characterized by the optic neuritis.

Moreover, many regulatory approvals such as FDA approvals for the development of novel therapeutics increase the trust in patients and show better results in optic neuritis treatment. For instance, on August 14, 2020, the FDA approved Genentech's Enspryng (satralizumab-mwge) as the first and only subcutaneous treatment for adults living with anti-aquaporin-4 (AQP4) antibody optic neuritis.

Further, the increasing prevalence of optic neuritis, increasing FDA approvals, increasing clinical trials, increasing awareness and advancements in the development of novel drugs and therapies are the factors expected to drive the market over the forecast period.

Restraints

Factors such as complications and side effects associated with the high doses of corticosteroids, the high cost of the treatment and lack of better treatment for the treatment are expected to hamper the market.

Segment Analysis

The global optic neuritis treatment market is segmented based on disease type, treatment type, distribution channel and region.

The intravenous corticosteroids segment accounted for approximately 45.3% of the optic neuritis treatment market share

The intravenous corticosteroids segment is expected to hold the largest market share over the forecast period. Intravenous corticosteroids are usually given to reduce the inflammation around the optic nerves. They can be given into a vein (infusion) for three days. These intravenous corticosteroids shorten the duration of the symptoms associated with the optic neuritis.

For instance, on April 05, 2022, Dr. Reddy's Laboratories, along with its subsidiaries, launched the Methylprednisolone Sodium Succinate for Injection, USP, the generic equivalent of SOLU-MEDROL (methylprednisolone sodium succinate for injection, USP) in the U.S. Market approved by the U.S. Food and Drug Administration for various types of inflammatory diseases and allergic disorders.

Further, their wide availability, acceptability, and, ease of application helps to hold the largest market share. The intravenous corticosteroids can also used by combining with oral steroids, these combining medications are considered especially in cases where a single drug modality may not be sufficient. In addition, their wide adoption for the treatment of optic neuritis also increases the demand for intravenous corticosteroids.

Geographical Analysis

North America accounted for approximately 39.2% of the market share

North America region is expected to hold the largest market share over the forecast period owing to the strong presence of major players and advanced healthcare facilities. North America especially the United States is well-known for its strong presence of major players such as pharmaceutical companies which are involved in the research and clinical activities for the treatment of optic neuritis, which leads to the launch of novel therapeutics and alternative treatment options.

Furthermore, the United States is also known for its well-established healthcare infrastructure including hospitals, ophthalmic centers, academic and research institutes and others, which provide advanced healthcare facilities for the treatment of optic neuritis. The increasing research activities also helps to develop more advanced therapeutics for the treatment of optic neuritis in the early stages.

Competitive Landscape

The major global players in the optic neuritis treatment market include: Pfizer Inc., MERCK & CO., Inc., EyePoint Pharmaceuticals, Inc., Novartis AG, Genentech, Inc., Mallinckrodt plc, Alcon Inc., NIKSAN PHARMACEUTICAL, AbbVie Inc. and Hubei Gedian Humanwell Pharmaceutical Co., Ltd. Among others.

COVID-19 Impact Analysis

The COVID-19 pandemic significantly impacted the global optic neuritis treatment market. During the pandemic, non-urgent treatments are temporarily postponed. The pandemic created unprecedented challenges for pharmaceutical industries worldwide, including the global optic neuritis treatment market by temporarily disrupting many clinical trials and research activities due to the redirected focus on the COVID-19 pandemic and its related restrictions. The pandemic also disrupted the supply chain of these treatment drugs globally.

Why Purchase the Report?

• To visualize the global optic neuritis treatment market segmentation based on disease type, treatment type, distribution channel and region as well as understand key commercial assets and players.
• Identify commercial opportunities by analyzing trends and co-development
• Excel data sheet with numerous data points of optic neuritis treatment market-level with all segments.
• PDF report consists of a comprehensive analysis after exhaustive qualitative interviews and an in-depth study.
• Product mapping available as excel consisting of key products of all the major players.

The global optic neuritis treatment market report would provide approximately 61 tables, 58 figures, and 187 Pages.

Target Audience 2023

• Manufacturers/ Buyers
• Industry Investors/Investment Bankers
• Research Professionals
• Emerging Companies

Table of Contents

1. Methodology and Scope

• 1.1. Research Methodology
• 1.2. Research Objective and Scope of the Report

2. Definition and Overview

3. Executive Summary

• 3.1. Snippet by Disease Type
• 3.2. Snippet by Treatment Type
• 3.3. Snippet by Distribution Channel
• 3.4. Snippet by Region

4. Dynamics

• 4.1. Impacting Factors
  • 4.1.1. Drivers
    • 4.1.1.1. Increasing Demand for Novel Therapeutics
  • 4.1.2. Restraints
    • 4.1.2.1. Complications Associated with the Use of Corticosteroids
  • 4.1.3. Opportunity
  • 4.1.4. Impact Analysis

5. Industry Analysis

• 5.1. Porter's Five Force Analysis
• 5.2. Supply Chain Analysis
• 5.3. Pricing Analysis
• 5.4. Regulatory Analysis
• 5.5. Pipeline Analysis
• 5.6. Unmet Needs
• 5.7. Patent Analysis
• 5.8. Volume Analysis
• 5.9. DMI Opinion

6. COVID-19 Analysis

• 6.1. Analysis of COVID-19
  • 6.1.1. Scenario Before COVID
  • 6.1.2. Scenario During COVID
  • 6.1.3. Scenario Post COVID
• 6.2. Pricing Dynamics Amid COVID-19
• 6.3. Demand-Supply Spectrum
• 6.4. Government Initiatives Related to the Market During the Pandemic
• 6.5. Manufacturers Strategic Initiatives
• 6.6. Conclusion

7. By Disease Type

• 7.1. Introduction
  • 7.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Disease Type
  • 7.1.2. Market Attractiveness Index, By Disease Type
• 7.2. Retrobulbar Neuritis*
  • 7.2.1. Introduction
  • 7.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
• 7.3. Papillitis
• 7.4. Perineuritis
• 7.5. Neuroretinitis

8. By Treatment Type

• 8.1. Introduction
  • 8.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment Type
  • 8.1.2. Market Attractiveness Index, By Treatment Type
• 8.2. Oral Corticosteroids*
  • 8.2.1. Introduction
  • 8.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
• 8.3. Intravenous Corticosteroids
• 8.4. Others

9. By Distribution Channel

• 9.1. Introduction
  • 9.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
  • 9.1.2. Market Attractiveness Index, By Distribution Channel
• 9.2. Hospital Pharmacies*
  • 9.2.1. Introduction
  • 9.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
• 9.3. Retail Pharmacies
• 9.4. Online Pharmacies

10. By Region

• 10.1. Introduction
  • 10.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region
  • 10.1.2. Market Attractiveness Index, By Region
• 10.2. North America
  • 10.2.1. Introduction
  • 10.2.2. Key Region-Specific Dynamics
  • 10.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Disease Type
  • 10.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment Type
  • 10.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
  • 10.2.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
    • 10.2.6.1. U.S.
    • 10.2.6.2. Canada
    • 10.2.6.3. Mexico
• 10.3. Europe
  • 10.3.1. Introduction
  • 10.3.2. Key Region-Specific Dynamics
  • 10.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Disease Type
  • 10.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment Type
  • 10.3.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
  • 10.3.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
    • 10.3.6.1. Germany
    • 10.3.6.2. UK
    • 10.3.6.3. France
    • 10.3.6.4. Italy
    • 10.3.6.5. Spain
    • 10.3.6.6. Rest of Europe
• 10.4. South America
  • 10.4.1. Introduction
  • 10.4.2. Key Region-Specific Dynamics
  • 10.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Disease Type
  • 10.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment Type
  • 10.4.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
  • 10.4.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
    • 10.4.6.1. Brazil
    • 10.4.6.2. Argentina
    • 10.4.6.3. Rest of South America
• 10.5. Asia-Pacific
  • 10.5.1. Introduction
  • 10.5.2. Key Region-Specific Dynamics
  • 10.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Disease Type
  • 10.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment Type
  • 10.5.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
  • 10.5.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
    • 10.5.6.1. China
    • 10.5.6.2. India
    • 10.5.6.3. Japan
    • 10.5.6.4. Australia
    • 10.5.6.5. Rest of Asia-Pacific
• 10.6. Middle East and Africa
  • 10.6.1. Introduction
  • 10.6.2. Key Region-Specific Dynamics
  • 10.6.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Disease Type
  • 10.6.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment Type
  • 10.6.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel

11. Competitive Landscape

• 11.1. Competitive Scenario
• 11.2. Market Positioning/Share Analysis
• 11.3. Mergers and Acquisitions Analysis

12. Company Profiles

• 12.1. Pfizer Inc.*
  • 12.1.1. Company Overview
  • 12.1.2. Product Portfolio and Description
  • 12.1.3. Financial Overview
  • 12.1.4. Key Developments
• 12.2. MERCK & CO., Inc.
• 12.3. EyePoint Pharmaceuticals, Inc.
• 12.4. Novartis AG
• 12.5. Genentech, Inc.
• 12.6. Mallinckrodt plc
• 12.7. Alcon Inc.
• 12.8. NIKSAN PHARMACEUTICAL
• 12.9. AbbVie Inc.
• 12.10. Hubei Gedian Humanwell Pharmaceutical Co., Ltd.

LIST NOT EXHAUSTIVE

13. Appendix

• 13.1. About Us and Services
• 13.2. Contact Us